Last edition
News about "Viatris "
Biocon Biologics Secures Global Rights to Hulio
The new agreement supersedes the existing collaboration agreement between Biocon Biologics and Fujifilm Kyowa Kirin Biologics (FKB) for biosimilar Adalimumab, under which Biocon Biologics only had commercialisation rights.
Viatris | 23/12/2025 | By News Bureau
Viatris to Receive USD 400 Million in Cash and USD 415 Million in Equity Shares of Biocon
Viatris is set to receive USD 400 million in cash and USD 415 million in Biocon equity shares as part of a revised agreement, accelerating the end of non-compete restrictions in the biosimilars space and enabling both companies to pursue expanded market opportunities.
Viatris | 08/12/2025 | By Dineshwori
Viatris Acquires Aculys Pharma, Secures Exclusive Rights to Pitolisant and Spydia in Japan
Viatris has completed the acquisition of Aculys Pharma, a clinical stage biopharmaceutical company focused on commercialising innovative treatments for neurological conditions.
Viatris | 16/10/2025 | By Dineshwori | 304
Viatris Names Andrew Enrietti Chief Administrative and Transformation Officer
Viatris Inc. has appointed Andrew Enrietti as its Chief Administrative and Transformation Officer – a newly created position.
Viatris | 20/08/2025 | By Dineshwori | 138
MPP-ViiV Agreement Expanded: Aurobindo, Cipla and Viatris to Make Generic HIV Drug Cabotegravir
ViiV Healthcare and the Medicines Patent Pool (MPP) have expanded their voluntary licensing agreement for cabotegravir, enabling manufacturers such as Aurobindo, Cipla, and Viatris to develop, manufacture, and supply generic versions for the HIV treatment in 133 countries.
Viatris | 15/07/2025 | By Dineshwori | 290
Nxera Pharma Assigns Japan Rights to Cenerimod for Autoimmune Diseases to Viatris
Nxera will receive an upfront payment of USD 10 million from Viatris and is eligible to receive a milestone payment upon regulatory approval of cenerimod in Japan plus royalties on net sales should it be commercialized in the assigned territories.
Viatris | 28/02/2025 | By Aishwarya | 433
Viatris Signs Licensing Deal with Lexicon Pharmaceuticals for Sotagliflozin
This licensing agreement leverages Viatris' expertise in cardiovascular diseases and its Global Healthcare Gateway, which offers partners ready access to more markets and patients worldwide through the company's unique global infrastructure and expertise.
Viatris | 18/10/2024 | By Aishwarya | 582
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy